Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced, it will present new clinical and pre-clinical data supporting its vision to extend the reach of cancer immunotherapies to new patient populations, in an oral presentation and four poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 3-5 November 2023, San Diego, CA.
| |
| [27-September-2023] |
| HOLON, Israel, Sept. 27, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present new clinical and pre-clinical data supporting its vision to extend the reach of cancer immunotherapies to new patient populations, in an oral presentation and four poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 3-5 November 2023, San Diego, CA. Oral presentation details: Abstract Title: Harnessing natural IL-18 activity through IL-18BP blockade reshapes the tumor microenvironment for potent anti-tumor immune response Poster presentation details: Abstract Title: Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701 + nivolumab +/- BMS-986207 in patients with platinum resistant ovarian cancer Abstract Title: Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer Abstract Title: Harnessing natural IL-18 activity through IL-18BP blockade reshapes the tumor microenvironment for potent anti-tumor immune response Abstract Title: The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer Compugen’s abstracts will be available on the publications section of Compugen’s website, www.cgen.com About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2 development by AstraZeneca through a license agreement for the development of bi-specific and multi-specific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The most advanced program, COM503 is in IND enabling studies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 to inhibit cancer growth in the tumor microenvironment. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact: Yvonne Naughton, Ph.D.
SOURCE Compugen Ltd. | ||
Company Codes: TelAviv:CGEN, NASDAQ-NMS:CGEN |
View original content:
